Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for cancer treatment. Genmab has two approved antibodies, DARZALEX® (daratumumab) for certain multiple myeloma indications and Arzerra® (ofatumumab) for certain chronic lymphocytic leukemia indications. Genmab is recruiting patients for clinical studies in solid tumors with the antibody-drug conjugates tisotumab vedotin and HuMax®-AXL-ADC. Genmab has a broad product pipeline and invented the DuoBody® and HexaBody® antibody technology platforms.